Rapport’s novel oral drug posts Phase II bipolar win

Rapport licensed the drug from J&J, which is also in the bipolar market with its $14.6bn deal-acquired drug Caplyta. Rapport licensed the drug from J&J, which is also in the bipolar market with its $14.6bn deal-acquired drug Caplyta. Bipolar disorder is a complex, lifelong condition which affects an estimated 37 million patients worldwide. Credit: izzuanroslan / Shutterstock.com Rapport Therapeutics’ Phase II bipolar mania study has met its primary endpoint, as it hopes to compete on the market with the drug’s original owner, Johnson & Johnson (J&J). In the study (NCT07046494), acute bipolar mania patients treated with RAP-219 achieved a 3.1-point…

Source: Clinical Trials Arena